Gilead hepatitis C drug shows promise in late-stage trial

(Reuters) - Gilead Sciences said a late-stage trial of its experimental hepatitis C treatment showed that the virus was not detected in 78 percent of patients taking the drug, 12 weeks after completing therapy. The trial, named Positron, was testing the drug, sofosbuvir, in patients who were unable or unwilling to take interferon -- a standard hepatitis C drug known for its unpleasant side effects. No patient in the placebo group achieved an undetectable virus level 12 weeks after completing the therapy, Gilead said. ... via Health News Headlines - Yahoo! News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2012/11/gilead-hepatitis-c-drug-shows-promise_27.html